Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Net Income: 2018-2024

Historic Net Income for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$257.6 million.

  • Allogene Therapeutics' Net Income rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
  • Per Allogene Therapeutics' latest filing, its Net Income stood at -$257.6 million for FY2024, which was up 21.29% from -$327.3 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Net Income peaked at -$250.2 million during FY2020, and registered a low of -$331.0 million during FY2022.
  • In the last 3 years, Allogene Therapeutics' Net Income had a median value of -$327.3 million in 2023 and averaged -$305.3 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 35.55% in 2020, then grew by 21.29% in 2024.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Net Income stood at -$250.2 million in 2020, then decreased by 2.71% to -$257.0 million in 2021, then declined by 28.78% to -$331.0 million in 2022, then climbed by 1.12% to -$327.3 million in 2023, then climbed by 21.29% to -$257.6 million in 2024.